Headache (see Headache, [[Headache]]): occurs in 8% of cases within 1 year
Otolaryngologic Adverse Effects
Nasopharyngitis (see Pharyngitis, [[Pharyngitis]])
Renal Adverse Effects
Hypertension (see Hypertension, [[Hypertension]]): occurs in 5% of cases within 1 year
Reproductive Adverse Effects
Teratogenicity
Other Adverse Effects
xxx
xxx
xxx
xxx
References
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365(12):1079-1087 [MEDLINE]
Anti-fibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmcol Exp Ther 2014;349:209-230 [MEDLINE]
Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med. 2014 Jul;108(7):1023-30. doi: 10.1016/j.rmed.2014.04.011. Epub 2014 Apr 29 [MEDLINE]
INPULSIS Trial: Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2071-82 [MEDLINE]
IPF: evolving concepts. Mayo Clin Proc 2014;9:1130-1142 [MEDLINE]
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015 May;45(5):1434-45. doi: 10.1183/09031936.00174914. Epub 2015 Mar 5 [MEDLINE]
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015 Sep 24;16:116. doi: 10.1186/s12931-015-0276-5 [MEDLINE]
Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis Across Pre-specified Subgroups in INPULSIS®. Am J Respir Crit Care Med. 2015 Sep 22 [MEDLINE]